Does 4-H Camp Influence Life Skill and Leadership Development?

WV conducted a two-phase study involving over 2,000 campers to learn how 4-H camp affects life skills and leadership development. Camp is at the heart of many states\u27 4-H programs; however, there is limited research to document the impact. Fifteen counties with 28 individual camps participated in the study, which measured (1) camp experience, (2) targeted Life Skills, and (3) leadership skills. The study found that 4-H experiential learning activities at camp positively affect campers\u27 life skills and leadership skills. Results should be used to guide the future measurement of 4 H camp impact and to strengthen camping curriculums

Differences in the Experiences of Boys and Girls in a Camp Environment

Between the ages of nine and twelve, key developmental differences exist between genders. Boys’ and girls’ brains simply develop in a different sequence (Sax, 2007) and at a different rate (Hanlon, et al., 1999). Since the 1970’s a tendency toward gender blindness and a lack of understanding about the real developmental differences between boys and girls may have limited the ability of youth professionals to best serve all youth. This paper highlights a study of whether boys and girls differ in camp experience and in life skill development as a result of camp? Fifteen counties with 28 individual camps participated in the study which measured (1) camp experience; (2) targeted life skills, and (3) leadership skills. The results showed significant differences between girls and boys. Researchers recommend that gender differences no longer be ignored when programming and that camp activities and curriculum meet the developmental needs of both boys and girls

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19

International audienc